Overview

An FDA inspection is no longer an event for which organizations can prepare only after receiving an inspection notice. Today, inspection readiness must be an ongoing part of the quality and compliance strategy. FDA uses risk-based approaches to determine where and how it directs inspectional resources, while inspections may range from routine surveillance and application-related inspections to for-cause, focused and targeted assessments. FDA may also use Remote Regulatory Assessments and other mechanisms to evaluate a firm’s records, processes and compliance posture. At the same time, FDA’s expectations increasingly extend beyond basic regulatory compliance. Investigators may examine whether procedures are actually followed, whether quality systems are effective, whether data are reliable and complete, whether investigations identify true root causes, and whether corrective actions prevent recurrence.

This comprehensive will provide a current, practical framework for preparing for an FDA inspection, managing the inspection professionally and responding strategically to observations and findings. Rather than focusing only on what to do when an investigator arrives, the program will examine the complete inspection lifecycle—from inspection readiness and internal risk assessment through investigator interactions, Form FDA 483 observations, CAPA, remediation and sustainable compliance. Participants will also explore how data integrity, electronic records, quality-system performance, employee preparedness and management oversight can influence the outcome of an FDA inspection.

Topics to Be Covered:

• Understanding the FDA inspection landscape in 2026
• Building an inspection-ready organization and facility
• What FDA investigators may examine during an inspection
• Preparing employees for investigator interactions and interviews
• Managing FDA document, data and information requests
• Identifying inspection vulnerabilities before they become observations
• Understanding and strategically responding to Form FDA 483 observations
• Recognizing data-integrity and quality-system risks
• Developing effective CAPA and remediation strategies
• Addressing systemic weaknesses and preventing repeat observations
• Considerations for drug, biologics and food-regulated organizations
• Moving from “inspection preparation” to continuous inspection readiness

Why Should You Attend?

An FDA inspection can have consequences far beyond the inspection itself. Poorly controlled records, ineffective investigations, unreliable data, repeat observations or inadequate responses can create significant regulatory and operational challenges. This webinar will help you move from inspection anxiety to inspection preparedness by providing a structured framework for understanding what FDA may examine and how your organization can demonstrate control.

You will learn how to:

• Identify inspection vulnerabilities before they become FDA observations
• Strengthen organizational and facility-level inspection readiness
• Prepare employees for FDA investigator interactions
• Manage document, data and interview requests effectively
• Recognize data-integrity risks before an inspection
• Evaluate Form 483 observations strategically
• Develop stronger responses, CAPAs and remediation plans
• Identify systemic quality-system weaknesses
• Prepare for both announced and evolving FDA assessment approaches
• Build an inspection-readiness culture that continues long after the investigator leaves

Most importantly, the webinar will help organizations shift from “preparing for an inspection” to “being inspection-ready every day.”

Who Will Benefit?

This webinar will be valuable for professionals responsible for FDA compliance, quality, manufacturing, regulatory affairs and inspection management, including:

• Regulatory Affairs professionals
• Quality Assurance and Quality Control professionals
• FDA Compliance professionals
• Pharmaceutical and Biotechnology professionals
• Food Safety and Quality professionals
• Manufacturing and Operations personnel
• Quality Unit personnel
• Laboratory and Analytical professionals
• Validation and Computerized Systems professionals
• Data Integrity professionals
• Supplier and Contract Manufacturing Quality professionals
• Clinical and Regulatory Compliance teams
• Facility and Site Managers
• Corporate Quality and Compliance leaders
• Senior Management and executives responsible for FDA-regulated operations

FDA inspection readiness is not simply about passing an inspection. It is about being able to demonstrate through people, processes, records, data and quality systems that your organization is consistently in control.

This webinar provides the practical framework to prepare for that scrutiny, manage the inspection with confidence and turn FDA findings into opportunities for stronger, more sustainable compliance.